Transcode Therapeutics IncNASDAQ:RNAZNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5250
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5110/ 221
- Ask / Lots0.5335/ 8
- Open / Previous Close0.0000 / 0.5250
- Day Range---
- 52 Week Range
- Volume57,404
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RNAZ |
|---|---|---|
| 09:32 ET | 1592 | 0.4399 |
| 09:48 ET | 200 | 0.4499 |
| 09:50 ET | 100 | 0.4499 |
| 09:52 ET | 800 | 0.445 |
| 09:56 ET | 4768 | 0.4493 |
| 10:03 ET | 500 | 0.449655 |
| 10:06 ET | 285 | 0.4493 |
| 10:08 ET | 2011 | 0.4493 |
| 10:10 ET | 2666 | 0.4408 |
| 10:12 ET | 636 | 0.445001 |
| 10:33 ET | 100 | 0.445 |
| 10:39 ET | 1050 | 0.4408 |
| 10:46 ET | 994 | 0.4408 |
| 10:50 ET | 100 | 0.4416 |
| 10:51 ET | 790 | 0.4416 |
| 10:53 ET | 410 | 0.440001 |
| 10:55 ET | 1180 | 0.44 |
| 11:11 ET | 1798 | 0.4401 |
| 11:18 ET | 100 | 0.4498 |
| 11:22 ET | 13977 | 0.4498 |
| 11:26 ET | 11121 | 0.4499 |
| 11:27 ET | 178 | 0.45 |
| 11:29 ET | 6410 | 0.45 |
| 11:31 ET | 1960 | 0.45 |
| 11:33 ET | 14810 | 0.4508 |
| 11:36 ET | 3040 | 0.4508 |
| 11:38 ET | 3795 | 0.455 |
| 11:45 ET | 2000 | 0.4599 |
| 11:47 ET | 1500 | 0.455049 |
| 11:49 ET | 6310 | 0.465 |
| 11:51 ET | 10289 | 0.45795 |
| 11:54 ET | 200 | 0.4699 |
| 11:56 ET | 979 | 0.4698 |
| 11:58 ET | 10526 | 0.451499 |
| 12:00 ET | 400 | 0.457 |
| 12:03 ET | 100 | 0.4569 |
| 12:09 ET | 450 | 0.457 |
| 12:14 ET | 319 | 0.456899 |
| 12:16 ET | 200 | 0.4569 |
| 12:20 ET | 2300 | 0.4485 |
| 12:32 ET | 2170 | 0.45345 |
| 12:34 ET | 2170 | 0.45345 |
| 12:45 ET | 112 | 0.4535 |
| 12:59 ET | 850 | 0.4565 |
| 01:01 ET | 1933 | 0.450568 |
| 01:32 ET | 100 | 0.46 |
| 01:39 ET | 5000 | 0.4609 |
| 01:42 ET | 300032 | 0.5 |
| 01:44 ET | 60589 | 0.497501 |
| 01:46 ET | 35793 | 0.485 |
| 01:48 ET | 30310 | 0.484 |
| 01:50 ET | 74211 | 0.4901 |
| 01:51 ET | 49023 | 0.4903 |
| 01:53 ET | 24022 | 0.504 |
| 01:55 ET | 19900 | 0.508199 |
| 01:57 ET | 22257 | 0.5044 |
| 02:00 ET | 27041 | 0.5063 |
| 02:02 ET | 5580 | 0.5 |
| 02:04 ET | 6917 | 0.5095 |
| 02:06 ET | 40763 | 0.51 |
| 02:08 ET | 18512 | 0.516699 |
| 02:09 ET | 2395 | 0.516161 |
| 02:11 ET | 12540 | 0.5155 |
| 02:13 ET | 8383 | 0.515405 |
| 02:15 ET | 6250 | 0.51275 |
| 02:18 ET | 4000 | 0.5155 |
| 02:20 ET | 271 | 0.5103 |
| 02:22 ET | 4795 | 0.52 |
| 02:24 ET | 8890 | 0.5102 |
| 02:26 ET | 4264 | 0.52 |
| 02:27 ET | 12291 | 0.5012 |
| 02:29 ET | 493 | 0.5012 |
| 02:31 ET | 9789 | 0.505 |
| 02:33 ET | 10197 | 0.505 |
| 02:36 ET | 4850 | 0.5085 |
| 02:38 ET | 5188 | 0.5108 |
| 02:40 ET | 7189 | 0.505 |
| 02:42 ET | 1493 | 0.51 |
| 02:44 ET | 4911 | 0.5107 |
| 02:45 ET | 2200 | 0.506 |
| 02:47 ET | 2408 | 0.5106 |
| 02:51 ET | 3729 | 0.51 |
| 02:54 ET | 702 | 0.511 |
| 02:58 ET | 1620 | 0.5189 |
| 03:02 ET | 1920 | 0.514 |
| 03:03 ET | 2300 | 0.519 |
| 03:05 ET | 669 | 0.5165 |
| 03:07 ET | 1300 | 0.5139 |
| 03:09 ET | 1046 | 0.5145 |
| 03:12 ET | 1995 | 0.51 |
| 03:14 ET | 103 | 0.5101 |
| 03:16 ET | 3861 | 0.5101 |
| 03:18 ET | 13678 | 0.5146 |
| 03:21 ET | 1236 | 0.5146 |
| 03:23 ET | 3739 | 0.5146 |
| 03:25 ET | 9693 | 0.5199 |
| 03:27 ET | 42288 | 0.53 |
| 03:30 ET | 17828 | 0.5378 |
| 03:32 ET | 2869 | 0.5357 |
| 03:34 ET | 1779 | 0.5262 |
| 03:36 ET | 8987 | 0.52 |
| 03:38 ET | 4891 | 0.5316 |
| 03:39 ET | 10198 | 0.5283 |
| 03:41 ET | 6940 | 0.5308 |
| 03:43 ET | 22462 | 0.5349 |
| 03:45 ET | 18939 | 0.5377 |
| 03:48 ET | 7845 | 0.5214 |
| 03:50 ET | 17331 | 0.515 |
| 03:52 ET | 14464 | 0.5249 |
| 03:54 ET | 2225 | 0.5151 |
| 03:56 ET | 18297 | 0.5179 |
| 03:57 ET | 5976 | 0.522 |
| 03:59 ET | 4684 | 0.525 |
Apr 16, 2024
DJ Transcode Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co., from 11:03AM ET on Tuesday Apr 16, 2024 by Dow Jones
11:03AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 15, 2024
Apr 3, 2024
DJ Transcode Therapeutics Price Target Maintained With a $3.00/Share by HC Wainwright & Co., from 12:14PM ET on Wednesday Apr 03, 2024 by Dow Jones
12:14PM ET on Wednesday Apr 03, 2024 by Dow JonesTransCode Therapeutics Reports 2023 Results; Provides Business Update, from 9:10AM ET on Wednesday Apr 03, 2024 by Dow Jones
9:10AM ET on Wednesday Apr 03, 2024 by Dow JonesPress Release: TransCode Therapeutics Reports 2023 Results; Provides Business Update, from 9:10AM ET on Wednesday Apr 03, 2024 by Dow Jones
9:10AM ET on Wednesday Apr 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Transcode Therapeutics Inc | 3.0M | 0.0x | --- |
Evolutionary Genomics Inc | 3.0M | -1.3x | --- |
Phio Pharmaceuticals Corp | 3.2M | -0.1x | --- |
Novelstem International Corp | 2.8M | -0.7x | --- |
Atreca Inc | 3.4M | 0.0x | --- |
GeoVax Labs Inc | 3.4M | -0.1x | --- |
Company Information
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
Contact Information
- Headquarters
- 6 Liberty Square, #2382BOSTON, MA, United States 02109
- Phone
- 857-301-6857
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Philippe Calais
- Interim President and Chief Executive Officer, Chief Financial Officer, Director
- Thomas Fitzgerald
- Chief Medical Officer
- Daniel Vlock
- Independent Director
- Erik Manting
- Independent Director
- Magda Marquet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-473.31 |
Book Value | $2.62 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
